Please login to the form below
TCR-T
This page shows the latest TCR-T news and features for those working in and with pharma, biotech and healthcare.
Boehringer Ingelheim and 3T Biosciences in cancer research agreement
The partnership will see Boehringer input its patient-derived T-cell receptor (TCR) data into 3T’s discovery platform, 3T TRACE, with the aim of identifying novel antigen targets for cancer ... TCR-T assets from Stanford University to rapidly expand
Latest news
-
AstraZeneca to acquire Neogene Therapeutics in $320m deal
AstraZeneca (AZ) has announced it will acquire Neogene Therapeutics, a clinical-stage biotech focused on the development of next-generation T-cell receptor therapies (TCR-T) for targeting solid tumours, in ... consideration. TCR-Ts are a relatively new
-
New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine
The newly modified T-cells were administered back into the body to detect tumour activity. ... The work highlighted at SITC and within the Nature paper paves the way for the continued advancement of research aimed at delivering safe and effective,
-
Roche bets on T-cell therapies with Adaptimmune deal
Given the turbulent history of T-cell field, this deal could mark a pivotal moment in cancer therapy. ... Adapatimmune is also involved in CAR-T and early in 2020 signed a deal with Astellas on both CAR-T and TCR allogeneic therapies.
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
BioNTech is looking to extend its presence in the cell therapy space, announcing a planned acquisition of Gilead company Kite’s solid tumour neoantigen T cell receptor (TCR) R&D platform ... This differs from CARs, which recognise antigens on the cell
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
Under the terms of the latest deal, Immatics will be in charge of taking the TCR projects through to the stage where a clinical candidate has been identified, with GSK taking ... TCR therapies are emerging as a new type of cell therapy that involves
More from news
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017
-
Deal Watch September 2016
1, 695. Medigene /Bluebird bio. Licence. Development and commercialisation of T cell receptor (TCR) immunotherapies against four targets, P1 ready, includes upfront of $15m. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies
-
Deal Watch February 2016
The ARCUS technology enables the production of CAR T-cells derived from healthy donors (i.e. ... licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting
-
Pharma deals in June 2015
therapeutic strategies, and initially on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies. ... Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell
-
Deal Watch table for June 2014
526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2). ... Collaboration. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
T and TCR-T cellular therapy pipeline across preclinical, regulatory and clinical development activities.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
